Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2023 - 2024)
Sagimet Biosciences has reported Liabilities and Shareholders Equity over the past 2 years, most recently at $174.8 million for Q3 2024.
- Quarterly results put Liabilities and Shareholders Equity at $174.8 million for Q3 2024, up 69.81% from a year ago — trailing twelve months through Dec 2024 was $558.3 million (up 152.47% YoY), and the annual figure for FY2023 was $96.7 million, changed.
- Liabilities and Shareholders Equity for Q3 2024 was $174.8 million at Sagimet Biosciences, down from $189.0 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for SGMT hit a ceiling of $194.5 million in Q1 2024 and a floor of $21.5 million in Q2 2023.